AIV Logo AIV Assistant

 Logo BioNTech SE - 0A3M.IL 117.50 USD

P/E
6.59
EPS
18.00
P/B
1.43
ROE
23.82
Beta
0.24
Target Price
219.54 USD

117.500 USD

117.500 USD

Daily: +3.52%
Key Metrics

P/E: 6.59

EPS: 18.00

Book Value: 83.02

Price to Book: 1.43

Debt/Equity: 1.03

% Insiders: 65.113%

Growth

Revenue Growth: -0.95%

Estimates

Forward P/E: 6.57

Forward EPS: 18.05

Target Mean Price: 219.54

 Logo About BioNTech SE - (0A3M.IL)

Country: Germany

Sector: Health Care

Website: http://www.biontech.de

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Exchange Ticker
IOB (United Kingdom) 0A3M.IL
BER (Germany) 22UA.BE
GER (Germany) 22UA.DE
DUS (Germany) 22UA.DU
HAM (Germany) 22UA.HM
MUN (Germany) 22UA.MU
SAO (Brazil) B1NT34.SA
VIE (Austria) BNTX.VI
MEX (Mexico) BNTXN.MX
NMS (United States) BNTX
FRA (Germany) 22UA.F
Historical Dividends
Year Total Dividends
2022 2.13 USD

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion